AcceleromicsHealth Insights
Practical guidance on regulation, clinical evidence, reimbursement, and privacy for digital health leaders.
Latest Perspectives from AcceleromicsHealth
Our team writes from direct experience advising health technology companies and practicing medicine. These short briefings distill the questions we hear most often from founders, product leaders, and investors.
Is your software a medical device? Answer it early.
Few decisions shape a digital health company’s trajectory as much as product classification. Whether your software is treated as a medical device determines your evidence burden, your development process, your time to market, and often the claims you are allowed to make in marketing materials. Yet many teams leave the question until late, after the product and its claims have already hardened.
We encourage founders to write down their intended use and indications for use before the first line of production code. From there, map the product against the relevant frameworks, including FDA guidance on Software as a Medical Device and clinical decision support, and the risk categorisation approaches used in the UK, the EU, and Asia-Pacific markets. A deliberate choice between a lower-risk, narrower claim today and a broader claim later can save a year or more.
Clinical validation that clinicians and payers will believe
A retrospective accuracy study is rarely enough. Health systems want to know whether your product improves outcomes, saves clinician time, or reduces cost in settings like theirs. Payers want the same evidence expressed in economic terms. Designing studies that answer those questions from the start is far cheaper than repeating them.
Strong validation plans define a clinically meaningful endpoint, a realistic comparator, and a population that reflects the patients who will actually use the product. They also plan for subgroup performance and generalisability, which are now routine questions for any algorithm-driven tool.
Treat reimbursement as a product feature
If nobody is paid when your product is used, adoption will depend entirely on goodwill. Reimbursement strategy belongs on the product roadmap, not just the sales plan. Existing billing codes for remote monitoring, telehealth, and care management may already cover part of your value proposition, provided your workflow and documentation are designed to support them.
Where no pathway exists yet, value-based contracts, employer and health plan partnerships, and health system licensing can bridge the gap while you build the evidence needed for broader coverage.
Privacy across borders: planning for more than one market
Health data is among the most regulated data in the world. A product built only around HIPAA may need significant rework to launch under GDPR in Europe or data protection laws in South Korea and elsewhere in Asia. Decisions about data residency, consent, de-identification, and vendor agreements are far easier to make once, at the architecture stage.
A privacy and security posture that satisfies the strictest market you plan to enter also becomes a commercial asset, shortening procurement reviews with hospitals and enterprise customers.
Designing for the clinical workflow, not around it
The best-performing tool will still fail if it adds clicks, alerts, or logins to an already overloaded clinical day. Before building, spend time observing the people who will use your product. Understand who acts on its output, when, and what they stop doing as a result.
Interoperability matters too. Standards such as HL7 FHIR and integration with the electronic health record are increasingly table stakes for enterprise buyers. Planning for them early prevents costly re-engineering later.
Stay Connected with AcceleromicsHealth
We share new perspectives, event updates, and commentary on health policy changes on LinkedIn. If there is a topic you would like us to cover, or you want a deeper briefing for your leadership team or board, get in touch.
Have a question we have not answered?
Our advisors can walk your team through the regulatory, clinical, and commercial questions specific to your product.